SecBot SecBot
8-K ·Filed May 7, 2026

DCTH

DELCATH SYSTEMS, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001628280-26-031725
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth is strong (+26% YoY) and the CHOPIN publication is a positive clinical catalyst, but the GAAP net income swing to a loss and declining adjusted EBITDA are headwinds. Monitor the Q2 2026 report for evidence that the Lancet publication is converting into accelerating procedure volume and margin improvement.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.24
T+0 close · May 7, 2026 · via day close
Latest settled
+16.01%
T+60 · $13.04
Vs SPY
+12.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $11.24entry
  2. T+1 · 6mo ago +2.14%α +1.31% · $11.48
  3. T+5 · 6mo ago +3.29%α +1.79% · $11.61
  4. T+20 · 6mo ago −8.10%α −11.23% · $10.33
  5. T+60 · 4mo ago +16.01%α +12.18% · $13.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Delcath Systems reported Q1 2026 revenue of $25.0M (+26% YoY), beating the $23.4M consensus, but posted a GAAP net loss of $1.1M vs net income of $1.1M a year ago. The company maintained its FY2026 revenue guidance of at least $100M and highlighted 36% HEPZATO volume growth and the CHOPIN trial publication in The Lancet Oncology as key catalysts.

Key Financial Metrics

EPS
−$0.03
est −$0.01 · -200.0%
Revenue
$25.0M
est $23.4M · +6.8% · +26.3% YoY
Rating
in line
Guidance
at least $100M
maintained
Gross Margin
85%

Key Facts

  • Q1 2026 total revenue of $25.0M, up 26% from $19.8M in Q1 2025
  • GAAP net loss of $1.1M vs net income of $1.1M in Q1 2025
  • GAAP diluted EPS of -$0.03 vs $0.03 in Q1 2025
  • Non-GAAP adjusted EBITDA of $3.4M, down from $7.6M in Q1 2025
  • FY2026 revenue guidance maintained at least $100M, gross margins 84%-87%
  • HEPZATO volume grew ~36% YoY in Q1 2026; 29 active treatment centers
  • CHOPIN Phase 2 trial results published in The Lancet Oncology
  • Cash and investments of $89.3M, no debt as of March 31, 2026
  • Repurchased 316,023 shares for ~$3.0M in Q1 2026 under $25M buyback program

Financial Impact

Revenue beat consensus by ~$1.6M (6.8%), but GAAP net income swung to a loss of $1.1M from a $1.1M profit a year ago. Adjusted EBITDA declined 55% to $3.4M.

revenueepsnet incomeadjusted EBITDA

Risk Factors

  • GAAP net loss and declining adjusted EBITDA vs prior year
  • FY2026 guidance of 'at least $100M' unchanged, no upward revision despite Q1 beat
  • R&D expenses nearly doubled YoY to $9.8M, pressuring profitability

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-031725
Document: dcth-20260507.htm0001628280-26-031725
Document: 0001628280-26-031725-index-headers.html0001628280-26-031725
Document: 0001628280-26-031725-index.html0001628280-26-031725
Document: 0001628280-26-031725.txt0001628280-26-031725
8-K Data (Synthetic)0001628280-26-031725

Track record

12 reports on DCTH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.22% at T+60 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $21.38 Now $19.87 −7.06% settles Feb 10
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $20.27 Now $19.87 −1.97% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $14.82 Now $19.87 +34.08% settles Feb 2
  4. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $14.86 Now $19.87 +33.71% settles Jan 26
  5. Oct 19, 202628d ago SC 13D/A Neutral 4/10 Entry $14.37 Now $19.87 +38.27% settles Jan 14
  6. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $11.77 to $16.48 Now $19.87 +68.89% ▲ +40.08% +35.68% vs SPY
  7. May 14, 202626w ago 8-K Neutral 3/10 Entry $11.46 to $16.67 Now $19.87 +73.39% ▲ +45.46% +41.87% vs SPY
  8. May 7, 202627w ago 8-K Neutral 5/10 Viewing Entry $11.24 to $13.04 Now $19.87 +76.78% ▲ +16.01% +12.18% vs SPY
  9. Apr 2, 202632w ago DEFA14A Neutral 3/10 Entry $9.63 to $12.59 Now $19.87 +106.33% ▲ +30.74% +16.58% vs SPY
  10. Mar 2, 202637w ago Insider Cluster Bullish 6/10 Entry $8.93 to $10.83 Now $19.87 +122.51% ▲ +21.28% +11.95% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026